Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts
<p>Abstract</p> <p>Background</p> <p>In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://www.molecular-cancer.com/content/10/1/111 |
id |
doaj-980bf98ae4b540b38d9c868bb3e4e699 |
---|---|
record_format |
Article |
spelling |
doaj-980bf98ae4b540b38d9c868bb3e4e6992020-11-25T00:46:07ZengBMCMolecular Cancer1476-45982011-09-0110111110.1186/1476-4598-10-111Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblastsvan der Burg Marja JMWiercinska ElizaVerlaan-de Vries MattyLodder KirstenTeunisse Amina FASde Lange JobLenos KristiaanSzuhai KarolyJochemsen Aart G<p>Abstract</p> <p>Background</p> <p>In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (MDMX/MDM4) are frequently overexpressed in wild-type p53 tumors. Whereas the main activity of hMDM2 is to degrade p53 protein, its close homolog hMDMX does not degrade p53, but it represses its transcriptional activity. Here we study the role of hMDMX in the neoplastic transformation of human fibroblasts and embryonic retinoblasts, since a high number of retinoblastomas contain elevated hMDMX levels.</p> <p>Methods</p> <p>We made use of an <it>in vitro </it>transformation model using a retroviral system of RNA interference and gene overexpression in primary human fibroblasts and embryonic retinoblasts. Consecutive knockdown of RB and p53, overexpression of SV40-small t, oncogenic HRasV12 and HA-hMDMX resulted in a number of stable cell lines representing different stages of the transformation process, enabling a comparison between loss of p53 and hMDMX overexpression. The cell lines were tested in various assays to assess their oncogenic potential.</p> <p>Results</p> <p>Both p53-knockdown and hMDMX overexpression accelerated proliferation and prevented growth suppression induced by introduction of oncogenic Ras, which was required for anchorage-independent growth and the ability to form tumors <it>in vivo</it>. Furthermore, we found that hMDMX overexpression represses basal p53 activity to some extent. Transformed fibroblasts with very high levels of hMDMX became largely resistant to the p53 reactivating drug Nutlin-3. The Nutlin-3 response of hMDMX transformed retinoblasts was intact and resembled that of retinoblastoma cell lines.</p> <p>Conclusions</p> <p>Our studies show that hMDMX has the essential properties of an oncogene. Its constitutive expression contributes to the oncogenic phenotype of transformed human cells. Its main function appears to be p53 inactivation. Therefore, developing new drugs targeting hMDMX is a valid approach to obtain new treatments for a subset of human tumors expressing wild-type p53.</p> http://www.molecular-cancer.com/content/10/1/111Transformation modelp53 pathwaytumorigenesishMDMXhMDM2retinoblastomaNutlin-3 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
van der Burg Marja JM Wiercinska Eliza Verlaan-de Vries Matty Lodder Kirsten Teunisse Amina FAS de Lange Job Lenos Kristiaan Szuhai Karoly Jochemsen Aart G |
spellingShingle |
van der Burg Marja JM Wiercinska Eliza Verlaan-de Vries Matty Lodder Kirsten Teunisse Amina FAS de Lange Job Lenos Kristiaan Szuhai Karoly Jochemsen Aart G Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts Molecular Cancer Transformation model p53 pathway tumorigenesis hMDMX hMDM2 retinoblastoma Nutlin-3 |
author_facet |
van der Burg Marja JM Wiercinska Eliza Verlaan-de Vries Matty Lodder Kirsten Teunisse Amina FAS de Lange Job Lenos Kristiaan Szuhai Karoly Jochemsen Aart G |
author_sort |
van der Burg Marja JM |
title |
Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
title_short |
Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
title_full |
Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
title_fullStr |
Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
title_full_unstemmed |
Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
title_sort |
oncogenic functions of hmdmx in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts |
publisher |
BMC |
series |
Molecular Cancer |
issn |
1476-4598 |
publishDate |
2011-09-01 |
description |
<p>Abstract</p> <p>Background</p> <p>In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (MDMX/MDM4) are frequently overexpressed in wild-type p53 tumors. Whereas the main activity of hMDM2 is to degrade p53 protein, its close homolog hMDMX does not degrade p53, but it represses its transcriptional activity. Here we study the role of hMDMX in the neoplastic transformation of human fibroblasts and embryonic retinoblasts, since a high number of retinoblastomas contain elevated hMDMX levels.</p> <p>Methods</p> <p>We made use of an <it>in vitro </it>transformation model using a retroviral system of RNA interference and gene overexpression in primary human fibroblasts and embryonic retinoblasts. Consecutive knockdown of RB and p53, overexpression of SV40-small t, oncogenic HRasV12 and HA-hMDMX resulted in a number of stable cell lines representing different stages of the transformation process, enabling a comparison between loss of p53 and hMDMX overexpression. The cell lines were tested in various assays to assess their oncogenic potential.</p> <p>Results</p> <p>Both p53-knockdown and hMDMX overexpression accelerated proliferation and prevented growth suppression induced by introduction of oncogenic Ras, which was required for anchorage-independent growth and the ability to form tumors <it>in vivo</it>. Furthermore, we found that hMDMX overexpression represses basal p53 activity to some extent. Transformed fibroblasts with very high levels of hMDMX became largely resistant to the p53 reactivating drug Nutlin-3. The Nutlin-3 response of hMDMX transformed retinoblasts was intact and resembled that of retinoblastoma cell lines.</p> <p>Conclusions</p> <p>Our studies show that hMDMX has the essential properties of an oncogene. Its constitutive expression contributes to the oncogenic phenotype of transformed human cells. Its main function appears to be p53 inactivation. Therefore, developing new drugs targeting hMDMX is a valid approach to obtain new treatments for a subset of human tumors expressing wild-type p53.</p> |
topic |
Transformation model p53 pathway tumorigenesis hMDMX hMDM2 retinoblastoma Nutlin-3 |
url |
http://www.molecular-cancer.com/content/10/1/111 |
work_keys_str_mv |
AT vanderburgmarjajm oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT wiercinskaeliza oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT verlaandevriesmatty oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT lodderkirsten oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT teunisseaminafas oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT delangejob oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT lenoskristiaan oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT szuhaikaroly oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts AT jochemsenaartg oncogenicfunctionsofhmdmxinitinvitroittransformationofprimaryhumanfibroblastsandembryonicretinoblasts |
_version_ |
1725266855024656384 |